论文部分内容阅读
目的:观察三七总苷单体成分人参皂苷Rbl对实验性肝纤维化的作用。方法:用50%四氯化碳造成大鼠肝纤维化模型,共35天,同时给予三七总皂苷单体成分人参皂苷Rbl治疗,于第5周(实验结束)时检测肝功能、血清Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、层黏连蛋白(LN),同时分离肝组织,光镜观察肝组织病理变化。结果:三七总皂苷能改善肝纤维化大鼠的肝功能,降低血清PCⅢ、HA、LN含量,明显减轻肝组织胶原的沉积,改善肝纤维化程度;而人参皂苷Rbl不能改善肝纤维化程度。结论:人参皂苷Rbl不具有抗肝纤维化的作用,人参皂苷Rbl不是三七总苷抗肝纤维化的有效成分。
Objective: To observe the effect of ginsenoside Rbl, a component of Panax notoginseng saponins, on experimental hepatic fibrosis. METHODS: Rat hepatic fibrosis model was established with 50% carbon tetrachloride for 35 days. At the same time, ginsenoside Rbl, a monomer component of Panax notoginseng, was administered. Liver function and serum III were measured at the 5th week (end of the experiment). Pre-collagen (PCIII), hyaluronic acid (HA), and laminin (LN) were also used to isolate liver tissue. Pathological changes of liver tissue were observed under light microscope. Results: Panax notoginseng saponins can improve the liver function of rats with hepatic fibrosis, reduce the content of serum PCIII, HA and LN, significantly reduce the deposition of collagen in liver tissue and improve the degree of hepatic fibrosis; while ginsenoside Rbl can not improve the degree of hepatic fibrosis. . Conclusion: Ginsenoside Rbl has no anti-hepatic fibrosis effect, and ginsenoside Rbl is not an active ingredient of Panax notoginseng saponin for hepatic fibrosis.